Ballentine Partners LLC Buys New Position in 10x Genomics $TXG

Ballentine Partners LLC bought a new stake in shares of 10x Genomics (NASDAQ:TXG) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 15,574 shares of the company’s stock, valued at approximately $180,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. ARK Investment Management LLC boosted its stake in 10x Genomics by 7.5% during the 1st quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company’s stock valued at $112,143,000 after purchasing an additional 901,656 shares during the period. Vanguard Group Inc. boosted its stake in 10x Genomics by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 11,118,086 shares of the company’s stock valued at $97,061,000 after purchasing an additional 184,537 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in 10x Genomics by 235.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock valued at $62,016,000 after acquiring an additional 4,987,195 shares in the last quarter. Millennium Management LLC raised its holdings in 10x Genomics by 434.5% in the 1st quarter. Millennium Management LLC now owns 5,377,492 shares of the company’s stock valued at $46,946,000 after acquiring an additional 4,371,327 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in 10x Genomics by 134.4% in the 1st quarter. AQR Capital Management LLC now owns 1,212,429 shares of the company’s stock valued at $10,585,000 after acquiring an additional 695,227 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

Wall Street Analysts Forecast Growth

TXG has been the subject of several recent research reports. Bank of America upped their price target on 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Thursday, June 26th. Wall Street Zen cut 10x Genomics from a “buy” rating to a “hold” rating in a report on Saturday, September 13th. Deutsche Bank Aktiengesellschaft set a $14.00 price target on 10x Genomics and gave the company a “hold” rating in a report on Friday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, September 13th. Finally, Canaccord Genuity Group set a $16.00 price target on 10x Genomics in a report on Monday, August 11th. Six analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $13.65.

10x Genomics Price Performance

TXG stock opened at $11.69 on Wednesday. The business has a fifty day moving average price of $13.25 and a 200 day moving average price of $10.96. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $22.55. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -16.70 and a beta of 2.00.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.63. The firm had revenue of $172.91 million during the quarter, compared to analysts’ expectations of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business’s revenue was up 12.9% on a year-over-year basis. During the same period last year, the firm posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 9,348 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the transaction, the chief executive officer directly owned 945,892 shares in the company, valued at approximately $13,043,850.68. This trade represents a 0.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the transaction, the insider owned 440,888 shares in the company, valued at $6,079,845.52. The trade was a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,149 shares of company stock worth $539,865. Insiders own 10.03% of the company’s stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.